New immunotherapy drug shows promise for advanced skin cancer
NCT ID NCT06981325
First seen Jan 12, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This phase 2 trial is testing the drug cemiplimab as a first treatment for people with advanced basal cell carcinoma, a type of skin cancer. The study will enroll 34 adults who have not received prior treatment with hedgehog inhibitors. Researchers want to see if cemiplimab can shrink tumors and control the cancer over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helios Klinikum Erfurt
RECRUITINGErfurt, Germany
-
Helios Klinikum Oberhausen
RECRUITINGOberhausen, Germany
-
Johannes Wesling Klinikum
RECRUITINGMinden, Germany
-
Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITINGHeidelberg, Germany
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Germany
-
Universitätsklinikum Leipzig
RECRUITINGLeipzig, Germany
-
Universitätsklinikum Tübingen
RECRUITINGTübingen, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (a cancer immunotherapy drug)
What this could lead to
If successful, this could offer a new first-line treatment option for advanced basal cell carcinoma, helping shrink tumors and control the disease without needing prior therapy.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The drug can cause immune-related side effects, and it may not work for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.